Cooper Companies Inc (NYSE:COO) – Equities researchers at Piper Jaffray Companies boosted their FY2019 earnings per share (EPS) estimates for Cooper Companies in a report issued on Thursday, May 30th. Piper Jaffray Companies analyst M. O’brien now forecasts that the medical device company will post earnings per share of $12.24 for the year, up from their previous forecast of $12.05. Piper Jaffray Companies currently has a “Overweight” rating and a $325.00 price target on the stock. Piper Jaffray Companies also issued estimates for Cooper Companies’ Q4 2019 earnings at $3.24 EPS, Q1 2020 earnings at $3.12 EPS, Q3 2020 earnings at $3.43 EPS, Q4 2020 earnings at $3.53 EPS and FY2020 earnings at $13.35 EPS.

COO has been the subject of several other reports. Zacks Investment Research cut shares of Cooper Companies from a “hold” rating to a “sell” rating in a report on Tuesday, February 5th. Wells Fargo & Co raised their target price on shares of Cooper Companies from $305.00 to $325.00 and gave the stock an “outperform” rating in a report on Wednesday, March 6th. Stephens raised their target price on shares of Cooper Companies from $305.00 to $320.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. KeyCorp raised their target price on shares of Cooper Companies from $296.00 to $314.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. Finally, Raymond James raised their target price on shares of Cooper Companies from $300.00 to $325.00 and gave the stock an “outperform” rating in a report on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. Cooper Companies currently has an average rating of “Buy” and a consensus price target of $306.30.

Cooper Companies stock opened at $297.79 on Monday. The company has a quick ratio of 0.75, a current ratio of 1.27 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $14.14 billion, a PE ratio of 25.89, a P/E/G ratio of 2.22 and a beta of 0.85. Cooper Companies has a 12-month low of $221.50 and a 12-month high of $302.36.

Cooper Companies (NYSE:COO) last posted its quarterly earnings data on Thursday, May 30th. The medical device company reported $2.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.76 by $0.18. The business had revenue of $654.30 million during the quarter, compared to analysts’ expectations of $655.00 million. Cooper Companies had a net margin of 16.46% and a return on equity of 17.54%. The business’s revenue was up 3.6% on a year-over-year basis. During the same period last year, the firm posted $2.86 earnings per share.

Several large investors have recently modified their holdings of COO. Norges Bank purchased a new stake in shares of Cooper Companies in the 4th quarter valued at approximately $117,156,000. Veritas Asset Management LLP lifted its position in shares of Cooper Companies by 77.8% in the 1st quarter. Veritas Asset Management LLP now owns 981,302 shares of the medical device company’s stock valued at $290,632,000 after acquiring an additional 429,340 shares in the last quarter. BlackRock Inc. lifted its position in shares of Cooper Companies by 7.1% in the 4th quarter. BlackRock Inc. now owns 3,732,729 shares of the medical device company’s stock valued at $949,981,000 after acquiring an additional 246,088 shares in the last quarter. Public Employees Retirement Association of Colorado lifted its position in shares of Cooper Companies by 481.9% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 196,798 shares of the medical device company’s stock valued at $50,085,000 after acquiring an additional 162,980 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of Cooper Companies by 4.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,834,318 shares of the medical device company’s stock valued at $839,449,000 after acquiring an additional 112,906 shares in the last quarter. Institutional investors and hedge funds own 96.22% of the company’s stock.

In related news, SVP Agostino Ricupati sold 2,400 shares of the company’s stock in a transaction that occurred on Friday, March 29th. The shares were sold at an average price of $296.13, for a total value of $710,712.00. Following the completion of the sale, the senior vice president now owns 400 shares in the company, valued at approximately $118,452. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Stanley Md Zinberg sold 740 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $290.03, for a total transaction of $214,622.20. Following the completion of the sale, the director now owns 17,421 shares of the company’s stock, valued at approximately $5,052,612.63. The disclosure for this sale can be found here. Insiders have sold 87,030 shares of company stock valued at $25,461,465 over the last 90 days. 1.70% of the stock is currently owned by insiders.

Cooper Companies Company Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Featured Article: What is a blue-chip stock?

Earnings History and Estimates for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.